Port-Saint-Louis-du-Rhône, France
Port-Saint-Louis-du-Rhône, France

Time filter

Source Type

Kandolf Sekulovic L.,Military Medical Academy | Peris K.,Catholic University of the Sacred Heart | Hauschild A.,University of Kiel | Stratigos A.,National and Kapodistrian University of Athens | And 32 more authors.
European Journal of Cancer | Year: 2017

Background Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among different European countries. We analysed the availability of these innovative therapies in Europe and estimated the number of patients without access to first-line recommended treatment per current guidelines of professional entities such as the European Society for Medical Oncology (ESMO), the European Organisation for Research and Treatment of Cancer (EORTC), the European Association of Dermato-Oncology (EADO), and European Dermatology Forum (EDF). Materials and methods Web-based online survey was conducted in 30 European countries with questions about the treatment schedules from 1st May 2015 to 1st May 2016: number of metastatic melanoma patients, registration and reimbursement of innovative medicines (updated data, as of 1st October 2016), percentage of patients treated and availability of clinical studies and compassionate-use programmes. Results The recommended BRAF inhibitor (BRAFi) + MEK inhibitor (MEKi) combination was both registered and fully reimbursed in 9/30 (30%) countries, and in 13/30 (43%) (all from Eastern Europe) not reimbursed. First-line immunotherapy with anti-PD1 antibodies was registered and fully reimbursed in 14/30 (47%) countries, while in 13/30 (43%) (all from Eastern Europe) not reimbursed. It was estimated that in Europe 19,600 patients with metastatic melanoma are treated, and 5238 (27%) do not have access to recommended first-line therapy. Significant correlation was found between human development index (HDI, UNDP report 2015), (r = 0.662; p < 0.001), health expenditure per capita (r = 0.695; p < 0.001) and the Mackenbach score of health policy performance (r = 0.765; p < 0.001) with the percentage of patients treated with innovative medicines and a number of reimbursed medicines. Conclusions Great discrepancy exists in metastatic melanoma treatment across Europe. It is crucial to increase the awareness of national and European policymakers, oncological societies, melanoma patients' associations and pharma industry. © 2017 Elsevier Ltd


Fouere S.,APHP Hospital Saint Louis | Lassau F.,APHP Hospital Saint Louis | Rousseau C.,Hospital Saint Louis | Bagot M.,APHP Hospital Saint Louis | Janier M.,APHP Hospital Saint Louis
International Journal of STD and AIDS | Year: 2016

We report the first case of chancroid seen at our clinic in 14 years. It was diagnosed by nuclear acid amplification test in a male patient returning from Madagascar. Although the disease is considered on the verge of disappearance even in tropical countries, its real potential for reemergence – due to new strains of Haemophilus ducreyi, underreporting and a lack of widespread use of molecular testing – could be underestimated. © 2016, © The Author(s) 2016.


PubMed | APHP Hospital Saint Louis and Hospital Saint Louis
Type: Journal Article | Journal: International journal of STD & AIDS | Year: 2016

We report the first case of chancroid seen at our clinic in 14 years. It was diagnosed by nuclear acid amplification test in a male patient returning from Madagascar. Although the disease is considered on the verge of disappearance even in tropical countries, its real potential for reemergence - due to new strains of Haemophilus ducreyi, underreporting and a lack of widespread use of molecular testing - could be underestimated.

Loading APHP Hospital Saint Louis collaborators
Loading APHP Hospital Saint Louis collaborators